Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2780301 + Paclitaxel in HER2-negative Breast Cancer
NCT01980277Phase 2Terminated
- Sponsor
- Institut Paoli-Calmettes
- Start
- Jan 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY2780301 in breast cancer, sponsored by Institut Paoli-Calmettes. Started Jan 2014; status: terminated.
02
Drugs
LY2780301
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01980277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01980277.